Giant cell arteritis

Displaying 6 studies

  • A Study of the Safety and Effectiveness of RoActemra/Actemra (Tocilizumab) for Patients with Giant Cell Arteritis Rochester, MN

    The purpose of this study is to evaluate the effectiveness and safety of RoActemra/Actemra (tocilizumab) for the treatment of patients who have giant cell arteritis.

  • A Study Testing the Effectiveness and Safety of KPL-301 in Patients with Giant Cell Arteritis Rochester, MN

    The primary purpose of this study is to evaluate the effectiveness and safety of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).

  • A Study to Evaluate Advanced Ultrasound Techniques for Diagnosis of Giant Cell Arteritis Rochester, MN

    The purpose of this study is to find out if advanced ultrasound studies can be used to make a diagnosis of giant cell arteritis. Ultimately, we hope to be able to offer non-invasive diagnostic options as an alternative to biopsy to future patients who are being evaluated for giant cell arteritis.


  • A Study to Understand Metalloproteinase-9 (MMP-9) and -12 (MMP-12) in Giant Cell Arteritis No Locations

    The purpose of this study is to gain more insight about the role of matrix metalloproteinase (MMP)-9 and -12 in the vascular remodeling in temporal arteries with giant cell arteritis (GCA), determine if their serum levels could be useful for diagnosis and/or follow up of patients with GCA, and determine if s single nucleotide polymorphisms (SNPs) of MMP-9 and/or MMP-12 could prove to be useful for diagnosis or prognosis.

  • A Study to Evaluate Abatacept to Treat Giant Cell Arteritis Rochester, MN

    The purpose of this study is to determine the effectiveness of abatacept in Giant Cell Arteritis (GCA).  Patients who have newly diagnosed or relapsing GCA within 8 weeks prior to screening will be randomized to receive subcutaneous abatacept or placebo.  All patients will receive glucocorticoids (GC) which will be tapered and discontinued by week 26 according to a standardized schedule. Patients who achieve remission will remain on their blinded assignment for 12 months at which time abatacept/placebo will be stopped. Patients who do not achieve remission by Month 3, who experience a relapse within the first 12 months, or who are ...

  • Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Rochester, MN

    The purpose of this clinical trial is to determine if low dose naltrexone is effective in improving health-related quality of life (HRQoL) among patients with vasculitis. Although it is a pilot study, a placebo-controlled component is used because of the prominent placebo group effect seen in studies with self-reported subjective outcomes.

    Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication. There are a few scientific studies in three conditions (fibromyalgia, Crohn's disease, and multiple sclerosis) ...


Mayo Clinic Footer